Takeda Pharmaceutical Company (TKDA) AI Stock Analysis

Company Guidance

For FY ’26, Takeda maintained management guidance for revenue of low single-digit percent decline at CER, raised its core operating profit forecast by JPY 30 billion to JPY 1.19 trillion from JPY 1.16 trillion, and raised core EPS guidance, mainly due to transaction FX benefits; revenue guidance on an absolute basis was raised by JPY 60 billion. The company expects a growth rebound in immunoglobulin in the second half, expects China to return to growth in the near term for albumin, and expects SCIG to sustain its strong growth and IVIG growth to accelerate, driven by the momentum of the large contracts in the U.S. The transformation program remains on track to achieve JPY 100 billion of gross savings, with JPY 160 billion of restructuring costs in FY ’26, JPY 10 billion less than the original forecast. Takeda expects to launch ORZEYFUL in the U.S. by early November, a potential U.S. launch of zasocitinib following the FDA approval decision planned in the fourth quarter of fiscal year 2026, a Phase IIb Crohn’s readout around the end of fiscal year 2026, TAK-360 results in Q4 of fiscal year 2026, and a TAK-921 regulatory filing in Japan during fiscal year 2027.